沙美特罗/氟替卡松治疗感染后咳嗽临床观察

目的探讨沙美特罗/氟替卡松（舒利迭）对感染后咳嗽治疗的临床疗效及安全性。方法前瞻性选择90例感染后咳嗽患者,随机分为三组：A组予以舒利迭吸入剂250μg吸入,2次/d;B组予以舒利迭100μg吸入,2次/d;C组予以右美沙芬混悬液10ml,3次/d。疗程均为10d。患者治疗前及治疗后均根据咳嗽症状积分表及视觉模拟评分体系进行评分,比较三组疗效及安全性。结果舒利迭治疗组（A、B组）疗效高于对照组（C组）而A组的优势更为明显（P〈0.05）。舒利迭治疗组不良反应少而轻微,与对照组比较无统计学差异（P〉0.05）。结论舒利迭（50/250μg）治疗感染后咳嗽疗效好而安全性高,值得临床推荐。

Clinical Efficacy of treatment with salmeterol/fluticasone propionate in patients with Post-infectious persistent cough

Objective To evaluate the clinical efficacy and security of treatment with salmeterol/fluticasone propionate（seretide） in patients with post-infectious persistent cough. Methods In this prospective, randomized study, a total of ninety patients with post-infectious persistent cough were divided into three groups. The patients in group A were treated with seretide 250μg twice daily, the patients in group B were treated with seretide 100μg twice daily, and the placebo in group C were treated with dextromethorphan sustained release suspension 10ml three times a day. The treatment term was 10 days. The efficacy was measured both by cough score and visual imitation scoring system（VAS）. The clinical efficacy and security were observed respectively. Results The treatment with seretide（group A and B） resulted in a greater reduction of cough frequency in patients with post-infectious persistent cough in comparison to placebo（group C） and the advantage of group A was more obvious. Few and mild sideeffects were observed in the three groups and had no difference（P〉0.05）. Conclusion Seretide（50/250μg） can be recommended as an effective and well tolerated therapeutic option in the treatment of post-infectious persistent cough.